SCHEMBL1008488

SCHEMBL1008488

O=C(O)C(CC1CCCC1)n1ncc(Oc2cc(F)ccc2F)cc1=O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.36
HIF1A Q16665 1/20 0.35
CHRM4 P08173 1/20 0.34
LPAR1 Q92633 3/20 0.33
LPAR5 Q9H1C0 3/20 0.33
MC4R P32245 1/20 0.33
FFAR1 O14842 1/20 0.33
CTSB P07858 1/20 0.33
CTSS P25774 1/20 0.33
BACE1 P56817 1/20 0.33
BACE2 Q9Y5Z0 1/20 0.33
CCR5 P51681 3/20 0.33
BRD4 O60885 1/20 0.33
BTK Q06187 1/20 0.33
EGLN1 Q9GZT9 1/20 0.32
PPARG P37231 1/20 0.32
PREP P48147 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008076 0.92 BRD4 (0.39) HIF1ACHRM4BRD4PREP
SCHEMBL1007288 0.91 LPAR1 (0.41) LPAR1LPAR5FFAR1CCR5EGLN1
SCHEMBL1010743 0.90 GCK (0.36) GCKMC4RFFAR1PPARG
SCHEMBL1008126 0.87 EGLN1 (0.42) HIF1ACHRM4LPAR1LPAR5FFAR1
SCHEMBL1008428 0.85 ABL1 (0.38) CCR5PPARG
SCHEMBL1008514 0.84 LPAR1 (0.38) HIF1ALPAR1LPAR5MC4RFFAR1
SCHEMBL1008556 0.84 HIF1A (0.37) GCKHIF1ABTKEGLN1
SCHEMBL1008265 0.83 FFAR1 (0.40) FFAR1BRD4EGLN1
SCHEMBL1008741 0.83 LPAR1 (0.39) LPAR1LPAR5
SCHEMBL1008391 0.83 LPAR1 (0.37) LPAR1LPAR5MC4REGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK GCK 1/4885HIF1A 3191/4885CHRM4 2753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.